Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents

• Published in: JACC. Cardiovascular interventions 2015-06, Vol.8 (7), p.889-899
• Main Authors: Sen, Hanim, MD, PhD, Lam, Ming Kai, MD, Löwik, Marije M., PhD, Danse, Peter W., MD, PhD, Jessurun, Gillian A.J., MD, PhD, van Houwelingen, K. Gert, MD, Anthonio, Rutger L., MD, PhD, Tjon Joe Gin, R. Melvyn, MD, Hautvast, Raymond W.M., MD, PhD, Louwerenburg, J. (Hans) W., MD, de Man, Frits H.A.F., MD, PhD, Stoel, Martin G., MD, PhD, van der Heijden, Liefke C., MD, Linssen, Gerard C.M., MD, PhD, IJzerman, Maarten J., PhD, Tandjung, Kenneth, MD, PhD, Doggen, Carine J.M., PhD, von Birgelen, Clemens, MD, PhD
• Format: Article
• Language: English
• Subjects: all-comer/all-comers; Cardiovascular; DES; drug-eluting-stents; EES; percutaneous coronary intervention; Promus Element platinum-chromium everolimus-eluting stent; randomized clinical trial; Resolute Integrity cobalt-chromium zotarolimus-eluting stent; ZES
• ISSN: 1936-8798
• DOI: 10.1016/j.jcin.2015.01.033

Abstract Objectives This study assessed clinical events and patient-reported chest pain 2 years after treatment of all-comers with Resolute Integrity zotarolimus-eluting stents (Medtronic Vascular, Santa Rosa, California) and Promus Element everolimus-eluting stents (Boston Scientific, Natick, Massachusetts). Background For both drug-eluting stents (DES), no all-comer outcome data from >12 months of follow-up have been published. Although there is increasing interest in patient-reported chest pain following stenting, data with novel DES are scarce. Methods The DUTCH PEERS multicenter trial (TWENTE II) (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial [TWENTE II]) randomized 1,811 all-comer patients to treatment with 1 type of DES. Monitoring and event adjudication were performed by independent contract research organizations. Results The 2-year follow-up of 1,810 patients (99.9%) was available. The primary composite endpoint target vessel failure occurred in 8.6% and 7.8% of patients treated with zotarolimus- and everolimus-eluting stents, respectively (p = 0.55). Rates of components of target vessel failure were: cardiac death (2.4% vs. 1.9%, p = 0.42); target vessel–related myocardial infarction (2.4% vs. 1.8%, p = 0.33); clinically-indicated target vessel revascularization (4.6% vs. 4.9%, p = 0.83). At 1- and 2-year follow-up, >80% of patients were free from chest pain (no between-stent difference). In addition, >87% of patients were either free from chest pain or experienced pain only at maximal physical exertion, but not during normal daily activities. Patients with chest pain after 12 months at no more than moderate physical effort had a higher risk of target vessel revascularization during the following year (hazard ratio: 1.89 [95% confidence interval: 1.05 to 3.39], p = 0.03). Conclusions During the second year of follow-up, the incidence of adverse clinical endpoints remained similar and low for both DES. The vast majority of patients were free from chest pain.